Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.97)
# 101
Out of 5,124 analysts
277
Total ratings
65.2%
Success rate
40.3%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Reiterated: Buy | $150 | $104.56 | +43.46% | 11 | Nov 10, 2026 | |
| SEPN Septerna | Reiterated: Buy | $46 → $60 | $50.74 | +18.25% | 4 | Nov 10, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $28 | $11.73 | +138.70% | 8 | Nov 9, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $68 | $31.24 | +117.67% | 9 | Nov 6, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | $133 | $90.00 | +47.78% | 14 | Nov 5, 2026 | |
| EVMN Evommune | Reiterated: Buy | $30 | $7.65 | +292.16% | 5 | Nov 5, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $123 → $131 | $109.00 | +20.18% | 21 | Nov 4, 2026 | |
| TRXB TRex Bio | Initiated Coverage: Buy | $39 | $13.59 | +186.98% | 1 | Nov 3, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Hold | $62 | $51.63 | +20.09% | 32 | Nov 3, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,282 → $1,200 | $962.27 | +24.71% | 32 | Oct 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $132 → $152 | $138.86 | +9.46% | 12 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $40.67 | +25.40% | 1 | Sep 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $47.97 | - | 12 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $328 → $326 | $259.85 | +25.46% | 17 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $6.55 | +571.76% | 6 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $15.60 | +156.41% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $30.19 | +32.49% | 19 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $57 | $35.15 | +62.16% | 17 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.19 | +320.17% | 4 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.50 | +233.33% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $39 | $7.27 | +436.45% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $4 | $4.24 | -5.66% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $13 → $19 | $12.62 | +50.55% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $0.7996 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $10.23 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $48.05 | n/a | 1 | Aug 8, 2023 |
Oruka Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $150
Current: $104.56
Upside: +43.46%
Septerna
Nov 10, 2026
Reiterated: Buy
Price Target: $46 → $60
Current: $50.74
Upside: +18.25%
Cullinan Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $28
Current: $11.73
Upside: +138.70%
Celldex Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $68
Current: $31.24
Upside: +117.67%
Dianthus Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $133
Current: $90.00
Upside: +47.78%
Evommune
Nov 5, 2026
Reiterated: Buy
Price Target: $30
Current: $7.65
Upside: +292.16%
Spyre Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $123 → $131
Current: $109.00
Upside: +20.18%
TRex Bio
Nov 3, 2026
Initiated Coverage: Buy
Price Target: $39
Current: $13.59
Upside: +186.98%
Travere Therapeutics
Nov 3, 2026
Reiterated: Hold
Price Target: $62
Current: $51.63
Upside: +20.09%
argenx SE
Oct 25, 2026
Reiterated: Buy
Price Target: $1,282 → $1,200
Current: $962.27
Upside: +24.71%
Sep 22, 2026
Reiterated: Buy
Price Target: $132 → $152
Current: $138.86
Upside: +9.46%
Sep 17, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $40.67
Upside: +25.40%
Sep 8, 2026
Rated: Hold
Price Target: n/a
Current: $47.97
Upside: -
Sep 1, 2026
Reiterated: Buy
Price Target: $328 → $326
Current: $259.85
Upside: +25.46%
Aug 13, 2026
Reiterated: Buy
Price Target: $44
Current: $6.55
Upside: +571.76%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $15.60
Upside: +156.41%
Aug 13, 2026
Reiterated: Buy
Price Target: $40
Current: $30.19
Upside: +32.49%
Aug 11, 2026
Reiterated: Buy
Price Target: $49 → $57
Current: $35.15
Upside: +62.16%
Jul 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.19
Upside: +320.17%
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $1.50
Upside: +233.33%
May 15, 2026
Reiterated: Buy
Price Target: $36 → $39
Current: $7.27
Upside: +436.45%
May 8, 2026
Reiterated: Hold
Price Target: $2 → $4
Current: $4.24
Upside: -5.66%
Mar 1, 2026
Reiterated: Hold
Price Target: $13 → $19
Current: $12.62
Upside: +50.55%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $0.7996
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $10.23
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $48.05
Upside: n/a